Summary
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project lies in enabling pharmaceutical companies to better evaluate and tailor treatments for inflammatory bowel disease (IBD), a chronic condition that affects over 3 million people in the United States. Drug development for IBD is hindered by the lack of scalable, non-invasive tools for monitoring disease activity and understanding patient variation. This project addresses that gap by developing a stool-based platform capable of capturing real-time molecular information about gut health. Unlike
